匯控(00005.HK)今起展開20億美元回購
匯豐控股(00005.HK)公布,與摩根士丹利已訂立多項不可撤回之非全權委託回購協議,讓摩根士丹利可於5月10日至9月30日期間,購買總值最多為20億美元之普通股,並同時向匯豐出售有關股份。
摩根士丹利將獨立於匯豐以外就回購相關事宜作出交易決定。購買普通股之行動將於倫敦證交所、Aquis交易所、Cboe Europe Limited(透過BXE及CXE交易委託賬本)及/或Turquoise(統稱英國地點)及/或香港聯交所進行。
所回購之普通股將被註銷。是項回購最多可購買19.97億股普通股,即根據2023年授權可回購之普通股數目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.